Advertisement

To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Multiple myeloma

TODAY'S HEADLINES

Top 5 things to know about new myeloma drug

By Christine Blank
In FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. Read more

Top 5 findings about IPF patients

by Christine Blank
Most idiopathic pulmonary fibrosis (IPF) patients have considerably impaired lung function and gastroesophageal reflux disease (GERD) is the most common comorbidity, according to initial results from the IPF-PRO Registry. Read more

CONTINUING EDUCATION

November 2015
Recognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis

Session code: 15DT36-KXF58

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this activity is to review the common medications associated with pulmonary toxicity and to review how to recognize and treat idiopathic pulmonary fibrosis.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT36-KXF58.
Copy the session code — 15DT36-KXF58  — before logging into the Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

EDITOR'S PICK

FDA OKs modified antihemophilic factor for hemophilia A

by Erin Bastick
FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have hemophilia A. Details

November 27, 2015

Related Articles

First-of-its kind myeloma drug approved

3 top concerns with IPF and comorbidities [SLIDESHOW]

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us